Cel-Sci (NYSEAMERICAN:CVM) Stock Price Down 4.4% – Time to Sell?
by Mitch Edgeman · The Markets DailyCel-Sci Corporation (NYSEAMERICAN:CVM – Get Free Report) fell 4.4% on Tuesday. The stock traded as low as $1.71 and last traded at $1.75. 224,569 shares traded hands during trading, a decline of 23% from the average session volume of 290,422 shares. The stock had previously closed at $1.83.
Cel-Sci Stock Performance
The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.42 and a current ratio of 1.48. The company has a market cap of $30.42 million, a P/E ratio of -0.18 and a beta of 0.58. The firm has a 50 day moving average price of $1.69 and a 200-day moving average price of $1.86.
Cel-Sci (NYSEAMERICAN:CVM – Get Free Report) last posted its earnings results on Friday, August 14th. The company reported ($0.47) earnings per share for the quarter.
Institutional Trading of Cel-Sci
A hedge fund recently raised its stake in Cel-Sci stock. Renaissance Technologies LLC increased its position in Cel-Sci Corporation (NYSEAMERICAN:CVM – Free Report) by 133.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 35,890 shares of the company’s stock after acquiring an additional 20,484 shares during the quarter. Renaissance Technologies LLC owned about 0.42% of Cel-Sci worth $115,000 at the end of the most recent quarter. 12.08% of the stock is currently owned by institutional investors.
Cel-Sci Company Profile
Cel-Sci Corporation is a clinical-stage biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company’s lead product candidate is Multikine (leukocyte interleukin, injection), an investigational immunotherapy designed to activate and direct the immune system against cancer cells. Its development has primarily focused on the treatment of locally advanced primary head and neck cancer.
Cel-Sci also develops therapies and vaccine candidates using its proprietary LEAPS technology platform.